Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

GENOMIC HEALTH, INC. (GHDX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
32.91(c) 32.45(c) 33.48(c) 31.4(c) 32.84 Last
395 878 250 835 176 399 306 263 179 492 Volume
+0.77% -1.40% +3.17% -6.21% +4.59% Change
More quotes
Financials ($)
Sales 2017 342 M
EBIT 2017 -5,51 M
Net income 2017 -2,40 M
Finance 2017 102 M
Yield 2017 -
Sales 2018 384 M
EBIT 2018 12,8 M
Net income 2018 11,9 M
Finance 2018 138 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 96,57
EV / Sales2017 3,10x
EV / Sales2018 2,68x
Capitalization 1 165 M
More Financials
Company
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions.It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable... 
Sector
Biotechnology & Medical Research
Calendar
11/28 | 04:30pmPresentation
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
02/22GENOMIC HEALTH : to Announce Fourth Quarter and Year-End 2017 Financial Results ..
PR
02/15GENOMIC HEALTH : Oncotype DX® Genomic Prostate Score™ Test Increases Use o..
AQ
02/05GENOMIC HEALTH : Oncotype DX® Genomic Prostate Score™ Test Increases Use o..
PR
2017GENOMIC HEALTH : to Present at the 36th Annual J.P. Morgan Healthcare Conference
PR
2017GENOMIC HEALTH : Presents New Data Demonstrating Value of Oncotype DX® to Optimi..
PU
2017GENOMIC HEALTH : Janssen Pharma Tie Up, GPS Test in Focus
AQ
2017GENOMIC HEALTH : and Cleveland Diagnostics Announce Strategic Collaboration to D..
AQ
2017BIOCENTURY - MANAGEMENT TRACKS : Sunesis, Vital
AQ
2017GENOMIC HEALTH INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal ..
AQ
2017GENOMIC HEALTH : Announces Research Collaboration with Janssen Pharmaceuticals t..
PR
More news
Sector news : Biotechnology & Medical Research - NEC
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
12:50aGenomic Health, Inc. $GHDX Insider Sells $162,295.28 in Stock  
02/22$GHDX New SEC Document(s) for Genomic Health, Inc. From our Stock News Alerts.. 
02/22Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results.. 
02/22$GHDX Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial R.. 
02/22Genomic Health : to Announce Fourth Quarter and Year-End 2017 Financial Resul.. 
More tweets
Qtime:60
News from SeekingAlpha
01/10YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides.. 
01/09Genomic Health (GHDX) Presents At 36th Annual J.P. Morgan Healthcare Conferen.. 
01/06Venture capital deals of the week 
2017Premarket analyst action - healthcare 
2017Midday Gainers / Losers 
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 32,7 $
Spread / Average Target -2,3%
EPS Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
G. Bradley Cole COO, CFO & Principal Accounting Officer
Steven Shak Chief Scientific Officer
Phillip G. Febbo Chief Medical Officer
Michael Vedda Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.-2.11%1 165
CELLTRION, INC.--.--%34 966
IQVIA HOLDINGS INC1.90%20 749
LONZA GROUP-6.95%19 587
INCYTE CORPORATION-10.56%17 877
NEKTAR THERAPEUTICS44.76%13 613